Less may be more: smaller lung surgery tested against standard for early cancer
NCT ID NCT07698990
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This phase 3 trial compares two surgical approaches for early-stage non-small cell lung cancer with small (≤2 cm), solid-dominant tumors located deep within the lung. One group receives segmentectomy, which removes only the affected segment of the lung, while the other receives lobectomy, which removes an entire lobe. The study aims to see if the less extensive surgery is as effective as the standard approach in terms of 5-year survival, potentially offering patients a lung-sparing option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Anatomic Segmentectomy
- What this could lead to
- If segmentectomy proves non-inferior, patients with small, deep lung tumors could undergo less extensive surgery, preserving more lung tissue and potentially improving recovery.
- What could go wrong
- This is a non-inferiority trial; segmentectomy might not be as effective as lobectomy in controlling cancer. The deep location of tumors could make segmentectomy technically challenging.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, 200030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can a radioactive tracer reveal whether immunotherapy is working?
- Can a new nucleotide analogue boost cancer treatment?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can standard cancer treatment wake up the immune system? a study investigates.